Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
23
LEGN Quote, Financials, Valuation and Earnings
Last price:
$23.58
Seasonality move
:
-4.18%
Day range:
$23.10 - $24.12
52-week range:
$20.21 - $45.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.66x
P/B ratio:
4.20x
Volume:
2.6M
Avg. volume:
2.3M
1-year change:
-27.98%
Market cap:
$4.3B
Revenue:
$627.6M
EPS (TTM):
-$1.31
Analysts' Opinion
-
Consensus RatingLegend Biotech Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $71.91, Legend Biotech Corp. has an estimated upside of 212.26% from its current price of $23.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $48.00 representing -108.42% downside risk from its current price of $23.60.
Fair Value
-
According to the consensus of 13 analysts, Legend Biotech Corp. has 212.26% upside to fair value with a price target of $71.91 per share.
LEGN vs. S&P 500
-
Over the past 5 trading days, Legend Biotech Corp. has overperformed the S&P 500 by 4.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Legend Biotech Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Legend Biotech Corp. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Legend Biotech Corp. reported revenues of $272.7M.
Earnings Growth
-
Legend Biotech Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Legend Biotech Corp. reported earnings per share of -$0.22.
Enterprise value:
3.7B
EV / Invested capital:
--
Price / LTM sales:
4.66x
EV / EBIT:
--
EV / Revenue:
4.03x
PEG ratio (5yr expected):
-1.33x
EV / Free cash flow:
-16.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$526.8M
Return On Assets:
-14.26%
Net Income Margin (TTM):
-26.42%
Return On Equity:
-23.01%
Return On Invested Capital:
-16.97%
Operating Margin:
-15.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $233.3M | $520.2M | $909.6M | $160.2M | $272.7M | |
| Gross Profit | $88.2M | $305.2M | $526.8M | $99.3M | $151.1M | |
| Operating Income | -$449.8M | -$351.2M | -$195.2M | -$70.4M | -$43.5M | |
| EBITDA | -$467.8M | -$329.3M | -$171.3M | -$64.9M | -$37.4M | |
| Diluted EPS | -$2.98 | -$1.91 | -$1.31 | -$0.68 | -$0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $653.4M | -- | $1.5B | $1.4B | $1.2B | |
| Total Assets | $813.8M | -- | $1.8B | $1.7B | $1.7B | |
| Current Liabilities | $275.4M | -- | $175.2M | $270.9M | $433.6M | |
| Total Liabilities | $586M | -- | $492.9M | $613.2M | $693.6M | |
| Total Equity | $225.9M | -- | $1.3B | $1.1B | $1B | |
| Total Debt | $73.5M | -- | $320.5M | $346.6M | $267.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$340M | -$152.5M | -$170.3M | -$75.1M | $28.9M | |
| Cash From Investing | -$297.1M | -$360.1M | -$16.6M | $328.5M | -$20.1M | |
| Cash From Financing | $789.8M | $7M | $14.7K | $4.2M | $671.5K | |
| Free Cash Flow | -$387.2M | -$238.8M | -$225M | -$92.5M | $15.2M | |
LEGN
Sector
Market Cap
$4.3B
$28.3M
Price % of 52-Week High
50.84%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-0.3%
-1.59%
1-Year Price Total Return
-29.72%
-17.41%
Beta (5-Year)
0.124
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$21.98
200-day SMA
Sell
Level
$32.45
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$22.19
Relative Strength Index (RSI14)
Buy
Level
50.39
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-6.9309
50-day SMA
Sell
Level
$26.61
MACD (12, 26)
Sell
Level
-1.12
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.845)
Sell
CA Score
(Annual)
Level (-0.4243)
Buy
Beneish M-Score
(Annual)
Level (-2.4758)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4823)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
Stock Forecast FAQ
In the current month, LEGN has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LEGN average analyst price target in the past 3 months is $71.91.
-
Where Will Legend Biotech Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Legend Biotech Corp. share price will rise to $71.91 per share over the next 12 months.
-
What Do Analysts Say About Legend Biotech Corp.?
Analysts are divided on their view about Legend Biotech Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Legend Biotech Corp. is a Sell and believe this share price will drop from its current level to $48.00.
-
What Is Legend Biotech Corp.'s Price Target?
The price target for Legend Biotech Corp. over the next 1-year time period is forecast to be $71.91 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LEGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Legend Biotech Corp. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LEGN?
You can purchase shares of Legend Biotech Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Legend Biotech Corp. shares.
-
What Is The Legend Biotech Corp. Share Price Today?
Legend Biotech Corp. was last trading at $23.58 per share. This represents the most recent stock quote for Legend Biotech Corp.. Yesterday, Legend Biotech Corp. closed at $23.60 per share.
-
How To Buy Legend Biotech Corp. Stock Online?
In order to purchase Legend Biotech Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LEGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LEGN
Sector
P/E ratio
--
24.24x
PEG ratio
-1.33x
-0.01x
P/B ratio
4.20x
1.84x
Price / LTM sales
4.66x
1.60x
Growth Metrics
LEGN
Sector
Revenue growth
70.21%
4.6%
Earnings growth
68.5%
10.71%
Revenue (5-year growth)
61.42%
6.45%
Earnings forecast
-$0.16
-$0.19
Profitability
LEGN
Sector
Profitability FY 2024
$369.5M
$3.5M
Return on invested capital
-16.97%
-32.04%
Return on assets
-14.26%
-28.44%
Return on equity
-23.01%
-38.09%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
11
Balance Sheet
LEGN
Sector
Total cash
$992.7M
$26.1M
Short term investments
$835.9M
$25.7M
Total assets
$1.7B
$76.4M
Long term debt
$267.4M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
